This is a routine medical conference data dump with no financial catalysts. ORLADEYO's core commercial story remains unchanged. Watch for Phase 3 navenibart (ALPHA-ORBIT) top-line data as the next binary catalyst, timing not stated in this release. No actionable trade signal from this filing alone.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $8.70entry
- T+1 · 5mo ago +4.14%α +2.37% · $9.06
- T+5 · 5mo ago +3.33%α +2.66% · $8.99
- T+20 · 4mo ago +20.11%α +18.34% · $10.45
- T+60 · 2mo ago +4.20%α +0.93% · $9.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained HAE attack reductions and a post hoc analysis of Phase 1b/2 navenibart data supporting ongoing Phase 3 evaluation. The press release contains no new revenue, earnings, or financial guidance, it is a clinical data update with routine positive framing.
Key Facts
- ORLADEYO 48-week data in pediatric HAE (APeX-P; n=29) showed median adjusted attack rate fell from 0.691/month (SOC) to 0.169/month on treatment.
- Attacks requiring professional care dropped from 22 (SOC 12wk) to 3 (first 12wk on ORLADEYO), reaching 0 in weeks 37-48.
- Phase 1b/2 ALPHA-STAR post hoc analysis (navenibart, n=29) showed consistent HAE attack reductions across baseline attack rate, BMI, and age subgroups.
- No severe or serious treatment-emergent adverse events reported for navenibart; most common TEAEs were headache, nasopharyngitis, and UTI.
- Multiple real-world evidence posters demonstrate ORLADEYO reduces healthcare utilization and improves patient satisfaction.
- No financial data, revenue, EPS, guidance, or material commercial updates were provided in this press release.
Financial Impact
No direct financial impact disclosed; clinical data updates support ongoing commercialization and pipeline value but do not change near-term revenue outlook for ORLADEYO.
Risk Factors
- No new commercial metrics or revenue guidance were provided, upside from this data is speculative.
- Navenibart Phase 3 results remain pending; could fail to replicate Phase 1b/2 findings in a larger, longer trial.
- Small n (29) and open-label design of APeX-P and ALPHA-STAR limit conclusiveness of these data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310979 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers